-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Antibody Drug Conjugate (ADC) for short A complex linked to a tumor-targeting monoclonal antibo.
Due to its outstanding performance in the treatment of tumors, pharmaceutical companies are accelerating their deployment in the ADC drug track in recent yea.
At present, more than 50 local companies have deployed ADC drugs, and about 60 ADC drugs are under research and developme.
It is worth noting that as the competition in the ADC drug track continues to intensify, more and more powerful pharmaceutical companies have begun to accelerate their overseas development through license o.
On July 26, Kelun Biotech, a subsidiary of Kelun Pharmaceutical, and Merck, a US pharmaceutical company, reached a cooperation agreement on ADC drugs for the treatment of solid tumors, authorizing the latter's global rights and interests in an early-stage biological macromolecule tumor project B; the agreement stipulated that, Colombo will receive an upfront payment of $35 million and milestone payments of up to $901 milli.
On July 28, CSPC announced that its subsidiary CSPC Jushi Bio entered into a licensing agreement with Elevation Oncology, an American biopharmaceutical company, to authorize the latter's global rights to an ADC drug targeting Claudin 12, excluding Greater Chi.
CSPC Jushi Bio will receive an upfront payment of $27 million, potential development and regulatory milestone payments of up to $148 million, and potential sales milestone payments of up to $02 billi.
The innovative antibody-drug conjugate (ADC) LM-302 was licensed to Turning Point in the United States, and Hebo Pharmaceuticals licensed the company's novel bispecific antibody HBM7022 generated from the company's HCAb-based immune cell engager (HBICE) platform to AstraZeneca for development and commercialization,e.
From the above point of view, it has become a trend for pharmaceutical companies to go overseas through license o.
In fact, under the background that the ADC drug market continues to expand and more and more companies increase their layout, it is an option for pharmaceutical companies to go overseas through license o.
.
This is mainly because the domestic ADC drugs have been very inten.
It is understood that in addition to the increasing number of companies entering the domestic ADC track, some targets are already very "crowde.
For example, HER2, including TOT BIOPHARM, Hengrui PHARMACEUTICAL, KELUN PHARMACEUTICALS, CSPC, and Lepu Biopharmaceuticals are all actively deployi.
According to relevant statistics, as of June 2022, domestic companies have applied for 64 new ADC drug clinical trials, and most of the current research projects focus on HER2, Trop-2 and other targe.
However, there are not many HER2 ADC and Trop-2 ADC projects independently developed in China that have reached the terminal clinical sta.
However, on the whole, the ADC track still has huge development potenti.
According to data from Frost & Sullivan, the global ADC drug market size is expected to reach US$2 billion in 2022, with an expected growth rate of 36% from 2019 to 2024, and the global ADC drug market size is expected to reach US$27 billion in 203 Among them, the market size of ADC drugs in China is expected to reach US$2 billion in 203 It is expected in the industry that with the continuous expansion of the market and the continuous improvement of the R&D strength of domestic innovative pharmaceutical companies, the number of new drug license-out transactions in China will continue to increase, and the amount of new drug projects will also hit new hig.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Due to its outstanding performance in the treatment of tumors, pharmaceutical companies are accelerating their deployment in the ADC drug track in recent yea.
At present, more than 50 local companies have deployed ADC drugs, and about 60 ADC drugs are under research and developme.
It is worth noting that as the competition in the ADC drug track continues to intensify, more and more powerful pharmaceutical companies have begun to accelerate their overseas development through license o.
On July 26, Kelun Biotech, a subsidiary of Kelun Pharmaceutical, and Merck, a US pharmaceutical company, reached a cooperation agreement on ADC drugs for the treatment of solid tumors, authorizing the latter's global rights and interests in an early-stage biological macromolecule tumor project B; the agreement stipulated that, Colombo will receive an upfront payment of $35 million and milestone payments of up to $901 milli.
On July 28, CSPC announced that its subsidiary CSPC Jushi Bio entered into a licensing agreement with Elevation Oncology, an American biopharmaceutical company, to authorize the latter's global rights to an ADC drug targeting Claudin 12, excluding Greater Chi.
CSPC Jushi Bio will receive an upfront payment of $27 million, potential development and regulatory milestone payments of up to $148 million, and potential sales milestone payments of up to $02 billi.
The innovative antibody-drug conjugate (ADC) LM-302 was licensed to Turning Point in the United States, and Hebo Pharmaceuticals licensed the company's novel bispecific antibody HBM7022 generated from the company's HCAb-based immune cell engager (HBICE) platform to AstraZeneca for development and commercialization,e.
From the above point of view, it has become a trend for pharmaceutical companies to go overseas through license o.
In fact, under the background that the ADC drug market continues to expand and more and more companies increase their layout, it is an option for pharmaceutical companies to go overseas through license o.
.
This is mainly because the domestic ADC drugs have been very inten.
It is understood that in addition to the increasing number of companies entering the domestic ADC track, some targets are already very "crowde.
For example, HER2, including TOT BIOPHARM, Hengrui PHARMACEUTICAL, KELUN PHARMACEUTICALS, CSPC, and Lepu Biopharmaceuticals are all actively deployi.
According to relevant statistics, as of June 2022, domestic companies have applied for 64 new ADC drug clinical trials, and most of the current research projects focus on HER2, Trop-2 and other targe.
However, there are not many HER2 ADC and Trop-2 ADC projects independently developed in China that have reached the terminal clinical sta.
However, on the whole, the ADC track still has huge development potenti.
According to data from Frost & Sullivan, the global ADC drug market size is expected to reach US$2 billion in 2022, with an expected growth rate of 36% from 2019 to 2024, and the global ADC drug market size is expected to reach US$27 billion in 203 Among them, the market size of ADC drugs in China is expected to reach US$2 billion in 203 It is expected in the industry that with the continuous expansion of the market and the continuous improvement of the R&D strength of domestic innovative pharmaceutical companies, the number of new drug license-out transactions in China will continue to increase, and the amount of new drug projects will also hit new hig.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
